AHCO:NSD-AdaptHealth Corp (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 29.17

Change

+0.56 (+1.96)%

Market Cap

USD 3.33B

Volume

1.11M

Average Target Price

USD 41.73 (+43.07%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; home medical equipment (HME) to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial payors. The company is headquartered in Plymouth Meeting, Pennsylvania.

Company Website : http://www.adapthealth.com

Address : 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Employees : 4,700

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 39.76

Short Ratio : 2.25

52 Week Low : 13.60

Shorted Shares : 3,255,730

200 Day Moving Average : 33.06

Shorted Shares Previous Month : 2,109,653

50 Day Moving Average : 34.75

Shares Held By Insiders : 318.83%

Short Percentage : 3.00%

Shares Held by Institutions : 49.83%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+0.10 (+0.02%)

 USD47.97B 27.05 95.73
PODD Insulet Corporation

+2.12 (+0.72%)

 USD19.53B 2,948.80 173.03
ABMD Abiomed, Inc

-7.06 (-2.09%)

 USD15.27B 76.95 58.90
LVGO Livongo Health, Inc

N/A

 USD14.20B N/A N/A
BRKR Bruker Corporation

-0.22 (-0.32%)

 USD10.29B 66.54 32.49
IART Integra LifeSciences Holdings ..

+1.30 (+1.83%)

 USD6.00B 45.19 25.09
TNDM Tandem Diabetes Care, Inc

+0.62 (+0.68%)

 USD5.72B N/A N/A
SWAV ShockWave Medical, Inc

-1.73 (-1.24%)

 USD4.91B N/A N/A
SDC SmileDirectClub, Inc

-0.21 (-2.03%)

 USD4.02B N/A N/A
LIVN LivaNova PLC

-1.44 (-1.74%)

 USD3.96B 77.40 N/A

ETFs Containing AHCO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.34% 10% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.34% 10% F 10% F
Trailing 12 Months  
Capital Gain 93.18% 61% D- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.18% 61% D- 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.64% 85% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.64% 85% B 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 88.38% 25% F 17% F
Risk Adjusted Return 58.43% 81% B- 77% C+
Market Capitalization 3.33B 88% B+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 98% A+ 94% A
Price/Book Ratio 10.40 35% F 17% F
Price / Cash Flow Ratio 17.03 23% F 27% F
EV/EBITDA 95.10 30% F 11% F
Management Effectiveness  
Return on Equity -32.93% 56% F 30% F
Return on Invested Capital 10.67% 92% A- 82% B-
Return on Assets 4.77% 92% A- 83% B
Debt to Equity Ratio 196.72% 11% F 9% F
Technical Ratios  
Short Ratio 2.25 59% F 49% F
Short Percent 4.02% 54% F 45% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.